Cellectar Biosciences (CLRB)
NASDAQ:CLRB
Want to see CLRB full AI Analyst Report?
Earnings Data
Report Date
Aug 19, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.48Last Year’s EPS
-3.39Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized major clinical progress for iopofosine (robust Phase IIb 12‑month data with high ORR, durable responses, and regulatory strategy toward accelerated approval) and an oversubscribed financing structure intended to fund late‑stage development. Operational progress on CLR125 and cost discipline were also highlighted. Key risks include a low pre‑financing cash balance, reliance on milestone‑contingent funding with market‑performance conditions, continued net losses, and tight timelines for Phase III initiation and regulatory milestones. On balance, the positive clinical data and financing momentum significantly outweigh the contingent funding and timing risks.Company Guidance
Positive 12‑Month CLOVER WaM Phase IIb Results
iopofosine I-131 met both primary and secondary endpoints in the 12‑month follow-up of the Phase IIb CLOVER WaM study (N=55). Key metrics: overall response rate (ORR) 83.6%, major response rate (MRR) 61.8%, median duration of response (DOR) 17.8 months, median progression-free survival (PFS) 13.5 months, VGPR/CR rate 14.5%, and disease control rate 98.2%. More than 30% of responders maintained responses beyond 36 months. Efficacy was consistent in both BTKi‑exposed and BTKi‑refractory subgroups.
Regulatory Pathway and Development Plans
Company plans to advance iopofosine toward an accelerated approval submission and initiate a randomized Phase III confirmatory trial evaluating PFS as the primary endpoint. Anticipated initiation of the Phase III study in late Q4 2026. Cellectar has Breakthrough Therapy designation from the FDA (received prior May), which the company expects could support an expedited review timeline and potential regulatory action in H2 2027 if milestones are met.
Oversubscribed Financing to Support Late‑Stage Development
Completed an oversubscribed financing structure providing up to $140 million (upfront $35 million plus up to $105 million in milestone‑based warrants). Company states this materially strengthens the balance sheet and provides resources to advance iopofosine through Phase III and potential commercialization, and to support the CLR125 TNBC program.
Advancement of CLR125 in Triple‑Negative Breast Cancer (TNBC)
Dosed first patients in the Phase Ib open‑label dose‑finding trial of CLR125 (alpha‑emitting radio conjugate) in relapsed/refractory TNBC. Trial will evaluate 3 dose levels, enroll ~15 patients per arm with an expansion cohort, and includes dosimetry and preliminary efficacy endpoints (RECIST, PFS). Company expects to report biodistribution, dosimetry and early efficacy data during the year.
Cost Discipline and Reduced Operating Expenses
R&D expenses for Q1 2026 were approximately $3.0M vs $3.4M in Q1 2025 (a decline of ~11.8%), driven by reduced follow‑up activities and lower preclinical spend (partially offset by increased manufacturing). G&A decreased to $2.8M vs $3.0M in prior year (~‑6.7%). Net loss narrowed to $5.7M ($1.33/share) from $6.6M ($4.30/share) in Q1 2025 (net loss reduction of ~13.6%; per‑share loss declined ~69.1%).
Scientific Recognition and Investor Visibility
Post‑BTKi subgroup analysis from CLOVER WaM was selected for presentation at ASCO, increasing scientific visibility. Management emphasized the potential for iopofosine to be a differentiated option in the post‑BTKi setting and possibly move earlier into the WM treatment paradigm.
CLRB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CLRB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2026 | $2.94 | $3.20 | +8.84% |
Mar 04, 2026 | $2.68 | $2.90 | +8.21% |
Nov 13, 2025 | $3.50 | $2.87 | -18.00% |
Aug 14, 2025 | $4.42 | $4.42 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Cellectar Biosciences (CLRB) report earnings?
Cellectar Biosciences (CLRB) is schdueled to report earning on Aug 19, 2026, TBA (Confirmed).
What is Cellectar Biosciences (CLRB) earnings time?
Cellectar Biosciences (CLRB) earnings time is at Aug 19, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CLRB EPS forecast?
CLRB EPS forecast for the fiscal quarter 2026 (Q2) is -0.48.